Opioid Postmarketing Studies Could Quantify “Doctor Shopping”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will hold two-day public meeting to get stakeholder input on how to design and conduct studies on serious risks of extended-release/long-acting opioids.
You may also be interested in...
Opioid Overprescribing: Can Physician Education Reverse It?
North Carolina county reports success in lowering opioid scrips during FDA public meeting on labeling for chronic pain, but little concrete data exists about what methods could be used to change doctor behavior.
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.